{"id":"W2892185075","doi":"10.1200/jco.2017.35.15_suppl.tps3105","title":"A multicenter, open-label, phase II study of PGG beta-glucan and pembrolizumab in patients (pts) with advanced melanoma (MEL) following progression on treatment with checkpoint inhibitors (CPI) or triple negative breast cancer (TNBC) failing front-line chemotherapy for metastatic disease.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Apotex (Canada)","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Triple-negative breast cancer; Immunotherapy; Phases of clinical research; Antigen; Immune system; Neutropenia; Metastatic breast cancer; Cancer; Breast cancer; Clinical trial; Immunology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005027541,0.0002502081,0.001076409,0.00007223698,0.0001817395,0.0000369087,0.0002673575,0.00007382332,0.000007287522],"category_scores_gemma":[0.0002954406,0.0001331136,0.0001333535,0.0000428796,0.0001449231,0.00004734306,0.0001166728,0.0001734189,1.071822e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002024292,"about_ca_system_score_gemma":0.0009906207,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003714883,"about_ca_topic_score_gemma":0.004667993,"domain_scores_codex":[0.9978265,0.0002189613,0.0009880462,0.0003998582,0.0002864886,0.0002802171],"domain_scores_gemma":[0.9973587,0.0001557682,0.001606457,0.0002929358,0.0002652546,0.0003208335],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3729194,0.04468985,0.1353617,0.00003429892,0.002090984,0.0002213622,0.0003509803,0.00003258167,0.0005765251,3.291094e-7,0.00002019863,0.4437018],"study_design_scores_gemma":[0.4392873,0.4455326,0.1086283,0.0004897544,0.00059714,0.000009098009,0.000437096,0.0001987683,0.004136322,0.000009539036,0.0004545219,0.000219466],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966913,0.0002456636,0.00002315293,0.0004978616,0.0001439675,0.002270884,0.0001133273,0.000001557375,0.00001224568],"genre_scores_gemma":[0.9973354,0.000445962,0.00167469,0.00006129703,0.000110743,0.0002542184,0.00002044512,0.00002892864,0.00006825629],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4434824,"threshold_uncertainty_score":0.5428213,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09115560599467787,"score_gpt":0.4964976122619084,"score_spread":0.4053420062672305,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}